Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289848 | 0.91 | L3MBTL1 (0.39) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL6291266 | 0.87 | L3MBTL1 (0.34) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL6290581 | 0.86 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL6290700 | 0.83 | CA12 (0.36) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL6428832 | 0.80 | KDM4E (0.34) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL6294334 | 0.80 | MAPT (0.38) | L3MBTL1SLC5A2POLBMAPTALDH1A1 | |
| SCHEMBL6293883 | 0.79 | LMNA (0.39) | L3MBTL1POLBMAPTALDH1A1GAA | |
| SCHEMBL6289835 | 0.76 | — | — | |
| SCHEMBL6294330 | 0.75 | — | — | |
| SCHEMBL6306683 | 0.70 | CA12 (0.37) | L3MBTL1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872711-B2 | β-substituted β-aminoethyl phosphonate derivatives | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2005-03-29 | — | — | US | claimed |
| EP-1330463-A2 | BETA-SUBSTITUTED BETA-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-07-30 | — | — | EP | claimed |
| US-20020111488-A1 | Beta-substitued beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002034756-A2 | BETA-SUBSTITUTED BETA-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-05-02 | — | — | WO | claimed |
| US-6872711-B2 | β-substituted β-aminoethyl phosphonate derivatives | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2005-03-29 | — | — | US | disclosed |
| EP-1330463-A2 | BETA-SUBSTITUTED BETA-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-07-30 | — | — | EP | disclosed |
| US-20020111488-A1 | Beta-substitued beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002034756-A2 | BETA-SUBSTITUTED BETA-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111488-A1 | Beta-substitued beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | L3MBTL1 666/4885CA12 4750/4885CA1 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.